Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia

Introduction of tyrosine kinase inhibitors for chronic myeloid leukemia treatment is associated with a 63% probability of maintaining a complete cytogenetic response, meaning that over 30% patients require an alternative methodology to overcome resistance, tolerance, or side effects. Considering the...

Descripción completa

Detalles Bibliográficos
Autores principales: Vinhas, Raquel, Fernandes, Alexandra R., Baptista, Pedro V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436101/
https://www.ncbi.nlm.nih.gov/pubmed/28624216
http://dx.doi.org/10.1016/j.omtn.2017.05.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436101/
https://www.ncbi.nlm.nih.gov/pubmed/28624216
http://dx.doi.org/10.1016/j.omtn.2017.05.003

Ejemplares similares